Open access
Sep 2026
Preclinical characterization of S095029, a novel clinical-stage Fc-attenuated NKG2A-blocking antibody for cancer immunotherapy
Results support the clinical development of S095029 in immuno-oncology-responsive tumour settings with adequate HLA-E expression and show that S095029 inhibited tumour growth by harnessing the anti-tumour activity of both NK and CD8+ T cells.
Maria C. Melander, Franziska Uhlenbrock, Anne Worsaae et al.
· Frontiers in Oncology · 0 citations